Tags : Neoantigen-Reactive


Kite and HiFiBio Signs a Research & License Agreement for

Shots: The collaboration is focused on developing technology for neoantigen-reactive T cell receptors (TCRs) to treat cancers, including solid tumor HiFiBio to get an upfront $10M with additional milestones payments and Kite will hold an exclusive option to license HiFiBiO’s single cell technology platform HiFiBio Therapeutics is focused on activating human immune system to fight […]Read More